Citi analyst Daniel Grosslight raised the firm’s price target on Cardinal Health (CAH) to $170 from $157 and keeps a Neutral rating on the shares. The company’s investor day showcased the significant progress it has made in bolstering its specialty solutions and accelerating its non-pharma growth areas, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- Buy Recommendation for Cardinal Health Driven by Strong Financial Outlook and Strategic Initiatives
- Cardinal Health price target raised to $180 from $175 at Evercore ISI
- Oracle reports Q4 beat, BioNTech to acquire CureVac: Morning Buzz
- Morning Movers: CureVac skyrockets after $1.25B deal to be acquired by BioNTech
- Cardinal Health Updates FY25 Outlook and FY26 Guidance
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue